Letrozol Farmoz

Letrozole, the active ingredient in Letrozol Farmoz, is an aromatase inhibitor presented as an oral tablet for oral administration. It lowers estrogen production and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, helping to slow tumor growth.

GNH USA supplies Letrozol Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Letrozol Farmoz is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Metastatic breast cancer: reduces tumor growth by lowering systemic estrogen levels. - Adjuvant therapy for early‑stage hormone receptor‑positive breast cancer: decreases risk of disease recurrence after surgery. - Neoadjuvant therapy in postmenopausal women: shrinks tumors before surgical resection.

Letrozole may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: feeling of stomach upset. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe bone loss or osteoporosis: increased fracture risk. - Cardiovascular events: such as deep‑vein thrombosis. - Liver function abnormalities: elevated enzymes. - Severe allergic reactions: including anaphylaxis. - Pulmonary embolism: blockage in lung arteries. - Elevated cholesterol levels: may affect lipid profile.

Before initiating Letrozol Farmoz, clinicians should consider several safety measures. - Monitor bone mineral density: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Assess cardiovascular risk: evaluate history of thromboembolic disease before starting therapy. - Check liver function: adjust use in patients with hepatic impairment. - Avoid use in pregnancy: Letrozole is contraindicated due to teratogenic risk (Category X). - Discontinue if severe adverse reactions occur: report to healthcare provider promptly. - Store at below 25°C: keep in the original container, protect from moisture and light.

Letrozol Farmoz can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with estrogen replacement therapy: negates therapeutic effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Tamoxifen: antagonistic hormonal effects; monitor clinical response. - Certain antidepressants (SSRIs): may affect estrogen metabolism; observe for side effects.